SS
TNXP icon

SBI Securities’s Tonix Pharmaceuticals TNXP Stock Holding History

SBI Securities’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.22K Buy
89
+13
+17% +$200 ﹤0.01% 2581
2025
Q4 		$1.19K Sell
76
-120
-61% -$2.21K ﹤0.01% 2584
2025
Q3 		$4.74K Buy
196
+39
+25% +$1.45K ﹤0.01% 2068
2025
Q2 		$5.65K Sell
157
-112
-42% -$2.94K ﹤0.01% 1929
2025
Q1 		$4.81K Buy
269
+231
+608% +$4.68K ﹤0.01% 1918
2024
Q4 		$1.24K Buy
+38
New +$790 ﹤0.01% 2512

Other funds holding TNXP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

SBI Securities's TNXP Position: Q1 2026 in Review

SBI Securities increased its Tonix Pharmaceuticals (TNXP) stake by 17% in Q1 2026, buying an estimated $200 and bringing the position to 89 shares worth $1.22K. The position accounts for ﹤0.01% of the portfolio, ranked #2581.

SBI Securities first reported a position in TNXP in Q4 2024 and has held it in 6 quarters since. The position peaked at $5.65K in Q2 2025. 81 funds tracked by Wall St. Rank hold TNXP as of Q1 2026.

  • SBI Securities held 89 shares of Tonix Pharmaceuticals worth $1.22K as of Q1 2026.
  • SBI Securities bought 13 Tonix Pharmaceuticals shares in Q1 2026, an estimated $200.
  • Tonix Pharmaceuticals made up ﹤0.01% of SBI Securities's portfolio in Q1 2026, its #2581 holding.
  • SBI Securities first reported a position in Tonix Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • SBI Securities's Tonix Pharmaceuticals position peaked at $5.65K in Q2 2025.
  • 81 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q1 2026.

Based on SBI Securities's 13F filing for Q1 2026, filed 28 Apr 2026.